EIN PRESSWIRE: A Press Release distribution service of EIN News

473 RELEASES POSTED IN LAST 24 HOURS
Share |

IMS Health to provide exclusive update on Biosimilar Developments

Principal Global Head Generics, IMS Health, to present a keynote address at the 5th annual Biosimilars and Biobetters Conference in London

A thoroughly interesting and very informative conference with excellent chairs and presenters. More of the same please
— Senior Manager, Abbott
LONDON, LONDON, UK, June 5, 2014 /EINPresswire.com/ -- Returning for its fitfth year and following on from the major success of previous events, SMI are proud to present the 5th annual Biosimilars & Biobetters Conference, 29th-30th September, 2014, London. With an in-depth focus on the current and future landscape of the biosimilars market, this meeting will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market.

The event programme includes unique case studies, presentations and round table discussions on the key issues surrounding biosimilar commercial and manufacturing developments.

Conference highlights include an opening address from Alan Sheppard, Principal Global Head Generics, Thought Leadership, IMS Health UK. His presentation “What is on the horizon?.. Reviewing the opportunities and challenges for the biopharmaceutical industry” will discuss the sustainability of the Biosimilar market and the barriers to market entry for biosimilars.

A snap shot of those who have confirmed attendance include Merck Serono, Univercells, Sanofi Aventis and BD Biosciences, plus many more at this year’s event.

Key speakers include: Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals; Catherine Akers, Regulatory Affairs Manager, Amgen Inc; Uwe Gudat, Head of Safety Biosimilars, Merck Switzerland Ltd; Michel Mikhail, Chief Regulatory Officer, Executive Vice President, Global regulatory - Governmental Relations, Fresenius Kabi; Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, Medimmune (AstraZeneca Biologics); Alok Sharma, Principal Scientist & Head Analytical Development, Lupin Laboratories Ltd plus many more.

Further information available to download online at www.biosimilars-biobetters.co.uk

For more information, contact Fateja Begum on +44 (0) 207 827 6184 or e-mail fbegum@smi-online.co.uk
Contact for media partners: Julia Rotar, jrotar@smi-online.co.uk


5th annual Biosimilars & Biobetters
29-30 September 2014
Holiday Inn Regents Park
London UK

About SMi:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.
We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries. More information can be found at http://www.smi-online.co.uk

Julia Rotar
SMi Group Ltd
+44 (0)20 7827 6168
email us here

Powered by EIN Presswire